|Day Low/High||4.14 / 4.31|
|52 Wk Low/High||2.15 / 5.78|
Investors in Vivus, Inc. saw new options become available today, for the November 8th expiration.
Once-Daily Extended-Release Qsymia Achieved 10% Weight Loss, Was Well Tolerated and Improved Blood Pressure
Investors in Vivus, Inc. saw new options become available today, for the November 1st expiration.
Trade-Ideas LLC identified Vivus (VVUS) as a "perilous reversal" (up big yesterday but down big today) candidate
Investors brace for a longer period of easy monetary policy as Janet Yellen is chosen as the next Fed chief.
Weight Loss With Qsymia Reduced Annualized Incidence Rate of Type 2 Diabetes Up to 78%
Hedge fund manager Gregory Taxin of Clinton Group talks about when companies hit a critical point that makes them ripe for activism.
Trade-Ideas LLC identified Vivus (VVUS) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Chris Lao, Kapitall:Â Biotech company VIVUS just named another new CEO, so who stands to benefit from the change? The resignation [...]
Stocks with insider trader activity include MIDD, VVUS, N, KS and RJF
New CEO Tony Zook has tough job, but investors optimistic.
This week, David Peltier answers questions from two subscribers about a pharmaceutical stock and a banking name.
An acceleration in Qsymia script growth started when Vivus gained access to retail pharmacies.
When Jefferies released a research note for Arena Pharmaceuticals (ARNA) with a target price of $12, shares subsequently fell to [...]
New Team Pledges Fast Action to Bring Anti-Obesity Drug Qsymia to More Patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.